Off-the-shelf NK cell therapy [WEBINAR]

For more information, visit: www.miltenyibiotec.com/applic... When Dr. Karl-Johan Malmberg was a grad student, one of his more skeptical mentors related treating cancer with immunotherapy to attempting to dry an ocean with a hairdryer - but as Dr. Malmberg will explain, it is one heck of a hairdryer, and we have one massive tool at our disposal in the immune system.
In this talk he will discuss the underlying mechanisms behind the functional diversification of human NK cells, strategies to selectively expand adaptive NK cells for off-the shelf NK cell therapy, and prospects for harnessing induced pluripotent stem cell (iPSC)-derived NK cells.
Tune in to discover more about the functional regulation of NK cells, and new insights into NK cell biology and cancer immunotherapy.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries - all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

[@lachiffre]

Excellent presentation, very clear and comprehensive. Thank you!

[@Zakariah1971]

Excellent

[@joeeastwood3795]

I understand that when Car-T therapy is used for chronic Lymphocytic Leukemia,it wipes out all B-cells,what about NK-cell therapy?Would it leave the heathy B-cells?

[@Miltenyi_Biotec]

Thank you for the question. NK cell-based therapeutic strategies in chronic lymphocytic leukemia (CLL) and in other malignancies aim to potentiate and/or restore NK cell activity or to provide patients with functional NK cells able to kill tumor cells. According to Sportoletti et al (NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications - PMC (nih.gov)) ‘’in vitro studies have shown that allogeneic NK cells, after expansion/activation with an optimized protocol, are able to kill CLL cells independently of KIR-HLA mismatches. However, although allogeneic NK cells do not mediate the GvL effect in a CLL-HSCT transplantation setting, they, unlike T cells, lack the potential to cause graft-versus-host disease (GvHD) thus representing appealing and safe candidates for adoptive immunotherapy for CLL.” Your Miltenyi Team